- Former
Eli Lilly Research Fellow Jeremy R. Graff, Ph.D., appointed as
President and Chief Development Officer to lead the Company’s
clinical development programs
- Eli
Lilly and Celgene veteran Jose Iglesias, M.D., joins as Consultant
Chief Medical Officer to drive the stenoparib program toward
regulatory approval
- Former
President of Novo Nordisk’s U.S. Operations, Jesper Høiland,
appointed as Strategic Advisor to guide strategic initiatives
and optimize commercial potential
Boston (October 3, 2024) — Allarity
Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a
clinical-stage pharmaceutical company dedicated to developing
personalized cancer treatments, today announced several key
leadership appointments to accelerate its clinical and strategic
development.
To further advance its clinical development efforts, Allarity
has appointed Jeremy R. Graff, Ph.D., as President and Chief
Development Officer. Dr. Graff, who has been a consultant to the
Company since December 2023, will now take on a more formal
leadership role. He brings over 25 years of experience in the
biotech and pharmaceutical industry, with a distinguished track
record in the development of targeted cancer therapies. During his
nearly 17-year tenure at Eli Lilly and Company, Dr. Graff
established and led the translational oncology group, advancing 31
clinical assets in the company’s oncology portfolio. Dr. Graff also
serves as a member of the Board of Directors of IN8bio, Inc., a
member of the Board of Trustees for the Wood Hudson Cancer Research
Laboratory, and is on the Scientific Advisory Board of Avicenna
Biosciences, Inc. Dr. Graff’s contributions to the field of
oncology are highlighted by his numerous patents and more than 60
publications, which have garnered over 22,000 citations. He
completed a post-doctoral fellowship at the Johns Hopkins
University School of Medicine. In his new role at Allarity, Dr.
Graff will continue to oversee the Company’s clinical development
programs, including the advancement of its dual PARP and Tankyrase
inhibitor, stenoparib, alongside Allarity’s Drug Response Predictor
(DRP®) companion diagnostic.
Dr. Graff commented, “I am honored to take on the role of
President and Chief Development Officer at Allarity Therapeutics.
Having worked closely with the team over the past year, I’ve seen
firsthand the tremendous potential of stenoparib, especially when
combined with the DRP. I look forward to continuing to drive our
clinical programs forward, leveraging our innovative approach to
personalized cancer treatment. Together, we will work to bring new
therapies to patients who urgently need them.”
Additionally, Allarity is pleased to announce the appointment of
Jose Iglesias, M.D., as Consultant Chief Medical Officer. Dr.
Iglesias, with over 35 years of global experience in the
pharmaceutical industry, will significantly enhance the Company’s
expertise in oncology clinical development. His appointment comes
as Allarity accelerates the stenoparib program’s path toward
regulatory approval for the treatment of advanced ovarian
cancer.
Dr. Iglesias has had a distinguished career spanning more than
35 years, working with both large pharma and biotech companies. His
career includes leadership roles at Biothera, Boston Biomedical,
Celgene Corporation, and Eli Lilly and Company. At Celgene, Dr.
Iglesias served as Vice President of Clinical Development, where he
oversaw the Phase III development of Abraxane for pancreatic
cancer, lung cancer, and metastatic breast cancer. He has designed
and led all phases of oncology clinical trials, including large
Phase III registration studies involving over 2,000 patients.
Throughout his career, Dr. Iglesias has made significant
contributions to oncology research, with his work extensively
published in oncology literature, amassing over 9,000 citations.
Dr. Iglesias graduated from medical school in 1986, completed
fellowships at both Duke University and University of Toronto, and
spent two years working in oncology clinics and private oncology
and hematology practice before transitioning into the
pharmaceutical industry.
Dr. Iglesias commented, “I am excited to join Allarity
Therapeutics as Consultant Chief Medical Officer at this crucial
time for the company. With over three decades in oncology drug
development, I’m eager to contribute to the advancement of
stenoparib and help navigate its path toward regulatory approval. I
believe in the potential of this innovative therapy to make a
significant difference for patients with advanced ovarian cancer,
and I look forward to working with the Allarity team to explore its
broader applications across other cancer types.”
In further strengthening its leadership team, Allarity has
appointed Jesper Høiland, the former President of Novo Nordisk’s
U.S. operations, as a key Strategic Advisor. Mr. Høiland’s global
pharmaceutical leadership experience will be instrumental in
advancing the Company’s strategic initiatives, particularly around
the anticipated commercialization of stenoparib.
Besides having been President for the U.S. organization of Novo
Nordisk, where he was responsible for pricing, product launches,
and infrastructure development, Mr. Høiland has also served as
President and CEO of Radius Health and as Global Commercial Officer
at Ascendis Pharma. Mr. Høiland’s board experience includes serving
on the boards of Concert Pharma and Leo Pharma, and his current
roles as Chairman at SciBase and Board Member at ALK. His academic
background includes a Master’s Degree in Management from Copenhagen
Business School and participation in prestigious leadership
programs at Harvard Business School, INSEAD, and IMD. Having lived
and worked in the U.S., Switzerland, Denmark, Australia, France,
Belgium, and Canada, Mr. Høiland brings a truly global perspective
to his role at Allarity.
Mr. Høiland commented, “I am impressed with the Allarity’s
management team and its technology, and I’m eager to contribute to
Allarity’s future development and strategic direction. With my
experience in global pharmaceutical leadership, I will help the
company realize the commercial potential of stenoparib and the DRP.
The company’s dedication to advancing personalized cancer
treatments aligns perfectly with my own values, and I look forward
to helping bring this innovative approach to cancer treatment to
patients around the world.”
Thomas Jensen, CEO of Allarity Therapeutics, commented on the
appointments: “We are thrilled to welcome Jeremy Graff, Jose
Iglesias, and Jesper Høiland to their new roles within Allarity.
Each brings a wealth of experience and proven leadership in their
respective fields, which will be instrumental as we continue to
advance stenoparib’s development. Dr. Graff’s deep expertise in
oncology drug development, combined with his track record in
advancing targeted cancer therapies, will be invaluable. Dr.
Iglesias’ extensive clinical oncology background will strengthen
our strategy and drive stenoparib toward regulatory approval.
Jesper Høiland’s insights from global pharmaceutical leadership,
particularly in financing and commercial strategy, will help us
optimize the commercial potential of the DRP and stenoparib. I am
confident their combined expertise will enhance our efforts to
bring innovative cancer therapies to patients in need.”
Allarity Therapeutics is actively advancing its lead program,
stenoparib, a novel dual-targeted inhibitor of PARP1/2 and
Tankyrase 1 and 2, has continued to demonstrate its potential as a
promising therapeutic option for patients with advanced ovarian
cancer.
About StenoparibStenoparib is an orally
available, small-molecule dual-targeted inhibitor of PARP1/2 and
Tankyrase 1 and 2. At present, tankyrases are attracting
significant attention as emerging therapeutic targets for cancer,
principally due to their role in regulating the Wnt signaling
pathway. Aberrant Wnt/β-catenin signaling has been implicated in
the development and progression of numerous cancers. By inhibiting
PARP and blocking Wnt pathway activation, stenoparib’s unique
therapeutic action shows potential as a promising therapeutic.
Allarity has exclusive global rights for the development and
commercialization of stenoparib, which was originally developed by
Eisai Co. Ltd. and was formerly known under the names E7449 and
2X-121.
About the Drug Response Predictor – DRP® Companion
DiagnosticAllarity uses its drug-specific DRP® to select
those patients who, by the gene expression signature of their
cancer, are found to have a high likelihood of benefiting from a
specific drug. By screening patients before treatment, and only
treating those patients with a sufficiently high, drug-specific DRP
score, the therapeutic benefit rate may be significantly increased.
The DRP method builds on the comparison of sensitive vs. resistant
human cancer cell lines, including transcriptomic information from
cell lines combined with clinical tumor biology filters and prior
clinical trial outcomes. DRP is based on messenger RNA expression
profiles from patient biopsies. The DRP® platform has proven its
ability to provide a statistically significant prediction of the
clinical outcome from drug treatment in cancer patients dozens of
clinical studies (both retrospective and prospective). The DRP
platform, which can be used in all cancer types and is patented for
more than 70 anti-cancer drugs, has been extensively published in
the peer-reviewed literature.
About Allarity TherapeuticsAllarity
Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage
biopharmaceutical company dedicated to developing personalized
cancer treatments. The Company is focused on development of
stenoparib, a novel PARP/Tankyrase inhibitor for advanced ovarian
cancer patients, using its DRP® companion diagnostic for patient
selection in the ongoing phase 2 clinical trial, NCT03878849.
Allarity is headquartered in the U.S., with a research facility in
Denmark, and is committed to addressing significant unmet medical
needs in cancer treatment. For more information, visit
www.allarity.com.
Follow Allarity on Social MediaLinkedIn:
https://www.linkedin.com/company/allaritytx/X:
https://twitter.com/allaritytx
Forward-Looking Statements This press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements provide the Company’s current expectations or forecasts
of future events. The words “anticipates,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,”
“possible,” “potential,” “predicts,” “project,” “should,” “would”
and similar expressions may identify forward-looking statements,
but the absence of these words does not mean that a statement is
not forward-looking. These forward-looking statements include, but
are not limited to, statements regarding the expected outcomes of
ongoing and future clinical trials for stenoparib, the potential
for achieving durable clinical benefits for patients, and the
Company’s strategic plans to pursue regulatory approvals for its
lead therapeutic candidate. Any forward-looking statements in this
press release are based on management’s current expectations of
future events and are subject to multiple risks and uncertainties
that could cause actual results to differ materially and adversely
from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not
limited to, Allarity’s ability to raise sufficient capital to
support its current and anticipated clinical trials, the risk that
early results of a clinical study do not necessarily predict final
results and that one or more of the clinical outcomes may
materially change following more comprehensive reviews of the data,
and as more patient data become available, the risk that results of
a clinical study are subject to interpretation and additional
analyses may be needed and/or may contradict such results, the
receipt of regulatory approval for stenoparib or any of our other
therapeutic candidates and companion diagnostics or, if approved,
the successful commercialization of such products, the risk of
cessation or delay of any of the ongoing or planned clinical trials
and/or our development of our product candidates, the risk that the
results of previously conducted studies will not be repeated or
observed in ongoing or future studies involving our therapeutic
candidates. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause our actual
results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in our Form S-1
registration statement filed on October 30, 2023, as amended and
our Form 10-K annual report on file with the Securities and
Exchange Commission (the “SEC”), available at the SEC’s website at
www.sec.gov, and as well as discussions of potential risks,
uncertainties and other important factors in the Company’s
subsequent filings with the SEC. All information in this press
release is as of the date of the release, and the Company
undertakes no duty to update this information unless required by
law.
###
Company Contact:
investorrelations@allarity.com
Media
Contact: Thomas
Pedersen Carrotize
PR &
Communications +45
6062 9390 tsp@carrotize.com
- Allarity Therapeutics - Press Release Allarity Strengthens
Leadership with Key Appointments
Allarity Therapeutics (NASDAQ:ALLR)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Allarity Therapeutics (NASDAQ:ALLR)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
